An interview with founder Mr. Chang-Hai Tsai, who is deeply involved in the biomedical field, focusing on three key business areas to build a comprehensive healthcare fleet.
Under the leadership of its founder, Mr. Chang-Hai Tsai, Ever-Supreme (6712) continues to innovate in new drug development, boldly challenging current medical bottlenecks, and collaborating with various spin-off companies to move towards a comprehensive health industry. The founder emphasizes that if Taiwan's biomedical development can effectively combine government resources, academic research, and industry funding, it not only has a great chance to cultivate the next Nobel laureate but also the opportunity to create a world-class biotech giant, allowing Taiwan's biotech industry to stand on the international stage.
Source of information：https://money.udn.com/money/story/5612/9217716